Physician profile
Manuel Gonzalez
NPI 1780640607
$12,262.48
in general payments reported to CMS, 2019-2025
43 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,703 · 2020: $1,817 · 2021: $2,380 · 2022: $1,776 · 2023: $1,901 · 2024: $1,088 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,587.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,098.09 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,805.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,702.44 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $1,606.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,101.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $704.73 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Impulse Dynamics (USA) INC. | $324.84 | 2022-2024 | Optimizer, Optimizer |
| Esperion Therapeutics, INC. | $229.65 | 2020-2021 | |
| Abbott Laboratories | $223.68 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $222.48 | 2019-2025 | |
| Exact Sciences Corporation | $214.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $181.37 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $175.44 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $165.44 | 2022-2023 | Ongentys |
| E.R. Squibb & Sons, L.L.C. | $139.96 | 2019-2025 | Eliquis |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.